|By PR Newswire||
|September 3, 2014 01:08 PM EDT||
- Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer
- AbbVie and Calico may co-invest up to $1.5 billion, utilizing Calico's discovery and early development capabilities and AbbVie's broad research, development and commercial expertise to advance innovative new therapies
NORTH CHICAGO, Illinois and SOUTH SAN FRANCISCO, California, Sept. 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer.
Calico is the Google-backed life sciences company that is led by Arthur D. Levinson Ph.D. (former chairman and CEO of Genentech) and Hal V. Barron, M.D. (former Executive Vice President and Chief Medical Officer of Genentech). The agreement paves the way for Calico to establish a world-class research and development facility in the San Francisco Bay Area.
Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases:
- Calico will use its scientific expertise to establish a world-class research and development facility, with a focus on drug discovery and early drug development
- AbbVie will provide scientific and clinical development support and its commercial expertise to bring new discoveries to market
"This collaboration demonstrates our commitment to exploring new areas of medicine and innovative approaches to drug discovery and development that augments our already robust pipeline," said Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie. "We are pleased to be working with such outstanding scientists as Art Levinson, Hal Barron and their team. The potential to help improve patients' lives with new therapies is enormous."
"Our relationship with AbbVie is a pivotal event for Calico, whose mission is to develop life-enhancing therapies for people with age-related diseases. It will greatly accelerate our efforts to understand the science of aging, advance our clinical work, and help bring important new therapies to patients everywhere," said Art Levinson, CEO and founder of Calico.
Details of the Research Collaboration
- AbbVie and Calico will each initially provide up to $250 million to fund the collaboration with the potential for both sides to contribute an additional $500 million
- Calico will be responsible for research and early development during the first five years and continue to advance collaboration projects through Phase 2a for a ten year period
- AbbVie will support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities
- Both parties will share costs and profits equally
"We are thrilled to have the opportunity to work with the many outstanding scientists at AbbVie to ensure that the important science at Calico is advanced quickly to benefit patients," said Hal Barron, M.D., President of Research and Development at Calico.
"We are extremely proud to have our research teams partnering with Calico as we aim to address treatments for diseases of aging," said Michael Severino, M.D., Executive Vice President, Research and Development, and Chief Scientific Officer, AbbVie. "Our broad R&D experience and capabilities will complement Calico's biotechnology expertise and innovative scientific approaches. Together, we are confident that we will bring new therapeutic solutions to patients."
Calico expects to begin filling critical positions immediately and plans to establish a substantial team of scientists and research staff in the San Francisco Bay Area.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
Calico (California Life Sciences LLC) is a Google-founded research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Visit www.calicolabs.com.
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2013 Annual Report on Form 10-K and in Item 1A, ''Risk Factors'' of Part II of AbbVie's second quarter 2014 Quarterly Report on Form 10-Q, which have been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Feb. 27, 2017 06:00 AM EST Reads: 6,146
Feb. 27, 2017 05:00 AM EST Reads: 7,405
Feb. 27, 2017 04:30 AM EST Reads: 2,231
Feb. 27, 2017 04:30 AM EST Reads: 4,297
Feb. 27, 2017 04:00 AM EST Reads: 7,346
Feb. 27, 2017 03:30 AM EST Reads: 2,202
Feb. 27, 2017 03:00 AM EST Reads: 2,485
Feb. 27, 2017 03:00 AM EST Reads: 2,293
Feb. 27, 2017 02:00 AM EST Reads: 7,548
Feb. 27, 2017 01:30 AM EST Reads: 1,953
Feb. 27, 2017 01:15 AM EST Reads: 1,714
Feb. 27, 2017 01:15 AM EST Reads: 1,682
Feb. 27, 2017 01:00 AM EST Reads: 2,153
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Feb. 27, 2017 01:00 AM EST Reads: 1,365
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Feb. 27, 2017 12:30 AM EST Reads: 8,846